| BIOA |
BioAge Labs, Inc. |
85%
|
Reciprocal relationship from BIOA graph: royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized under the Novartis Agreement in the three m… |
| GLUE |
Monte Rosa Therapeutics, Inc. |
85%
|
Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: pany has identified certain performance obligations within the agreement as… |
| RGNX |
REGENXBIO Inc. |
85%
|
Reciprocal relationship from RGNX graph: . (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the development and commercialization of treatments for spinal muscular … |
| BNBX |
BNB Plus Corp. |
72%
|
Reciprocal relationship from BNBX graph: t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as en… |
| CRNX |
Crinetics Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement … |
| CTMX |
CytomX Therapeutics, Inc. |
72%
|
Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our work… |
| CYTK |
Cytokinetics, Incorporated |
72%
|
Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subse… |
| GKOS |
Glaukos Corporation |
72%
|
Reciprocal relationship from GKOS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GKOS graph: compete with many companies, including divisions of companies much larger t… |
| IMNM |
Immunome, Inc. |
72%
|
Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement a… |
| INCY |
Incyte Corporation |
72%
|
Reciprocal relationship from INCY graph: (in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ … |
| IRIX |
IRIDEX Corporation |
72%
|
Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| KMDA |
Kamada Ltd. |
72%
|
Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: sell products in the Distribution segment in Israel, we must register the p… |
| LEGN |
Legend Biotech Corporation |
72%
|
Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN… |
| LNTH |
Lantheus Holdings, Inc. |
72%
|
Reciprocal relationship from LNTH graph: ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been off… |
| LQDA |
Liquidia Corporation |
72%
|
Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA… |
| MLTX |
MoonLake Immunotherapeutics |
72%
|
Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX… |
| PLRX |
Pliant Therapeutics, Inc. |
72%
|
Reciprocal relationship from PLRX graph: pearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the … |
| PTCT |
PTC Therapeutics, Inc. |
72%
|
Reciprocal relationship from PTCT graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from PTCT… |
| RDY |
Dr. Reddy's Laboratories Limited |
72%
|
Reciprocal relationship from RDY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RDY graph: ell lung cancer following the results of the futility analysis. As a result, … |
| REGN |
Regeneron Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from REGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from REGN graph: on, patient education, reimbursement and market access, trade and distribut… |
| SDGR |
Schrödinger, Inc. |
72%
|
Reciprocal relationship from SDGR graph: e software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access our cl… |
| SLGL |
Sol-Gel Technologies Ltd. |
72%
|
Reciprocal relationship from SLGL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from SLGL… |
| TCRX |
TScan Therapeutics, Inc. |
72%
|
Reciprocal relationship from TCRX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from TCRX graph: ver $ million, based upon the achievement of certain clinical development a… |
| TGTX |
TG Therapeutics, Inc. |
72%
|
Reciprocal relationship from TGTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX… |
| VOR |
Vor Biopharma Inc. |
72%
|
Reciprocal relationship from VOR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VOR gr… |
| VYGR |
Voyager Therapeutics, Inc. |
72%
|
Reciprocal relationship from VYGR graph: pon certain terminations for cause by Novartis, the licenses granted by the Company to Novartis under the 2022 Novartis Agreement shall become irrevocable and… |
| XNCR |
Xencor, Inc. |
72%
|
Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of Decemb… |
| ZBIO |
Zenas BioPharma, Inc. |
72%
|
Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier,… |
| ZVRA |
Zevra Therapeutics, Inc. |
72%
|
Reciprocal relationship from ZVRA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZVRA… |
